AnaptysBio Reports $76.3M Collaboration Revenue and Plans Strategic Separation

AnaptysBio, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company achieved collaboration revenue of $76.3 million for the third quarter, a substantial increase from $30.0 million in the same period last year. For the nine months ending September 30, 2025, total collaboration revenue reached $126.4 million, compared to $48.2 million for the same period in 2024. This growth was primarily driven by milestone payments and royalties from its collaboration with GSK, particularly related to the sales of the PD-1 antagonist, Jemperli.

Operating expenses for the third quarter decreased to $41.6 million from $52.8 million year-over-year, reflecting a reduction in research and development costs, which fell from $42.2 million to $31.4 million. The decrease in R&D expenses was attributed to lower clinical expenses and outside services for manufacturing. Despite these reductions, the company reported a net income of $15.1 million for the quarter, a turnaround from a net loss of $32.9 million in the prior year. For the nine-month period, however, AnaptysBio recorded a net loss of $62.8 million, an improvement from a loss of $123.4 million in the same timeframe last year.

In terms of strategic developments, AnaptysBio announced plans to separate its operations into two independent publicly traded companies. This separation aims to create one entity focused on managing royalties and milestones from GSK and Vanda Pharmaceuticals, while the other will concentrate on developing its clinical-stage pipeline, including rosnilimab, ANB033, and ANB101. The separation is expected to be completed by the end of 2026, pending board approval and regulatory conditions.

Operationally, AnaptysBio's cash and cash equivalents totaled $109.8 million as of September 30, 2025, down from $123.1 million at the end of 2024. The company reported a decrease in total assets to $353.1 million from $483.8 million, largely due to reduced cash reserves and investments. The company’s employee headcount remained stable, with no significant changes reported. AnaptysBio continues to focus on advancing its clinical trials, with ongoing studies for rosnilimab in rheumatoid arthritis and ulcerative colitis, and ANB033 in celiac disease.

Looking ahead, AnaptysBio anticipates continued fluctuations in collaboration revenue based on the timing of milestones and product sales from its partners. The company believes its current resources will support operations for at least the next 12 months, although it may seek additional financing to support its growth and development initiatives. The management remains optimistic about the potential of its product candidates and the strategic separation, which is expected to enhance shareholder value.